ストックスクリーナーアプリを入手
1.1749
26.03%
0.2386
前日終値:
$0.9363
開ける：
$0.95
24時間の取引高:
876.32K
Relative Volume:
3.18
時価総額：
$32.01M
収益：
-
当期純損益:
-
株価収益率:
-13.32
EPS:
-0.0882
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-40.70%
1か月 パフォーマンス:
+101.67%
6か月 パフォーマンス:
-89.50%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.95
$1.30
1週間の範囲:
$0.90
$1.59
52週間の値動き範囲:
$0.51
$19.51
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
名前
Jupiter Neurosciences Inc
セクター
電話
(561) 406-6154
住所
1001 NORTH US HWY 1, JUPITER
JUNS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
1.21 | 32.01M | 0 | 0 | 0 | -0.0882 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.53 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.20 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.30 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.88 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jupiter Neurosciences Inc (JUNS) 最新ニュース
Jupiter Neurosciences’ Innovative Strategy in Biotech: A Dual Approach to Success - citybuzz -
How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success - FinancialContent
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Jupiter Neurosciences launches Nugevia longevity products By Investing.com - Investing.com South Africa
Jupiter Neurosciences launches resveratrol-powered supplements - Longevity.Technology
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Jupiter Neurosciences launches Nugevia longevity products - Investing.com
Jupiter Neurosciences Launches Nugevia™: A Premium - GlobeNewswire
Jupiter Neurosciences Targets $8T Longevity Market with Revolutionary 9x More Effective Supplement Line - Stock Titan
IsoEnergy Announces Launch of At-The-Market Equity Program - The Globe and Mail
Certain Restricted Stock Units of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Certain Common Stock of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Certain Options of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
Jupiter Neurosciences appoints new auditor amid transition By Investing.com - Investing.com Nigeria
Jupiter Neurosciences appoints new auditor amid transition - Investing.com Australia
Jupiter Neurosciences targets Parkinson’s and longevity markets By Investing.com - Investing.com South Africa
Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development - marketscreener.com
Jupiter Neurosciences targets Parkinson's and longevity markets - Investing.com
Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant - Stock Titan
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com India
Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire
Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks
Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa
Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com
Jupiter Neurosciences partners with Aquanova on health products - Investing.com
Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Inc (JUNS) 財務データ
収益
当期純利益
現金流量
EPS
1.59%
0.56%
大文字化:
|
ボリューム (24 時間):